相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder
Jonas van Ham et al.
ACTA CLINICA BELGICA (2021)
Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin
Hossein Esmaeilzadeh et al.
CLINICAL IMMUNOLOGY (2021)
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
Elena E. Perez et al.
FRONTIERS IN IMMUNOLOGY (2021)
A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
Hidefumi Kato et al.
FRONTIERS IN IMMUNOLOGY (2021)
Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency
Dandan Luo et al.
CLINICAL THERAPEUTICS (2020)
Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases
Jonas Graf et al.
ACTA NEUROLOGICA SCANDINAVICA (2019)
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents
Daniel Suez et al.
IMMUNOTHERAPY (2019)
Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease
Waqar Waheed et al.
MUSCLE & NERVE (2019)
A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates
Susan Bauer et al.
JOURNAL OF INFUSION NURSING (2019)
Adverse Effects of Immunoglobulin Therapy
Yi Guo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases
Hans D. Ochs et al.
IMMUNOTHERAPY (2018)
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra (R) Studies
Rajiv Mallick et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2018)
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmuneA®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency
Gergely Krivan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2017)
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (PanzygaA®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
Michael Borte et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2017)
Evaluation of the Safety, Tolerability, and Pharmacokinetics of GammaplexA® 10% Versus GammaplexA® 5% in Subjects with Primary Immunodeficiency
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2017)
A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID)
J. -F. Viallard et al.
REVUE DE MEDECINE INTERNE (2017)
Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence
Patrick Cherin et al.
AUTOIMMUNITY REVIEWS (2016)
Efficacy and safety of Gammaplex® 5% in children and adolescents with primary immunodeficiency diseases
I. R. Melamed et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
FlebogammaA® 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases
Mark Ballow et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Evidence-Based Strategies to Reduce Intravenous Immunoglobulin-Induced Headaches
Krisy-Ann Thornby et al.
ANNALS OF PHARMACOTHERAPY (2015)
Practice parameter for the diagnosis and management of primary immunodeficiency
Francisco A. Bonilla et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease
G. Krivan et al.
VOX SANGUINIS (2015)
Clinical picture and treatment of 2212 patients with common variable immunodeficiency
Benjamin Gathmann et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov-NCT00504075)
Clive H. Dash et al.
PLOS ONE (2014)
Is dosing of therapeutic immunoglobulins optimal? A review of a three-decace long debate in Europe
Jacqueline Kerr et al.
FRONTIERS IN IMMUNOLOGY (2014)
Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies
K. Bleasel et al.
INTERNAL MEDICINE JOURNAL (2012)
Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency
Marianne B. Empson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Kiovig for primary immunodeficiency: Reduced infusion and decreased costs per infusion
Mark Connolly et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseases
J. N. Moy et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Intravenous immunoglobulins - understanding properties and mechanisms
A. Durandy et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency
C. G. M. Kallenberg
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)